Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians.

Banerjee, Rahul; Wang, Bo; Anderson, Larry D; McCaughan, Georgia; Mehra, Nikita; Cowan, Andrew J; Rajkumar, S Vincent; Kaur, Gurbakhash

Banerjee, Rahul; Wang, Bo; Anderson, Larry D; McCaughan, Georgia; Mehra, Nikita; Cowan, Andrew J; Rajkumar, S Vincent; Kaur, Gurbakhash.

Afiliación

Banerjee R; Department of Medicine, University of Washington, Seattle, WA, USA. rahul.banerjee.md@gmail.com.
Wang B; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. rahul.banerjee.md@gmail.com.
Anderson LD; Willamette Valley Cancer Institute, Eugene, OR, USA.
McCaughan G; Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
Mehra N; Department of Haematology, St Vincent's Hospital, Sydney, NSW, Australia.
Cowan AJ; Garvan Institute of Medical Research, University of New South Wales, Sydney, NSW, Australia.
Rajkumar SV; Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, India.
Kaur G; Department of Medicine, University of Washington, Seattle, WA, USA.

Blood Cancer J ; 13(1): 162, 2023 11 06.

Article en En | MEDLINE | ID: mdl-37926718

Asunto(s)

Mieloma Múltiple; Médicos; Humanos; Bortezomib/uso terapéutico; Mieloma Múltiple/tratamiento farmacológico; Nivel de Atención; Pirazinas

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Médicos / Mieloma Múltiple Límite: Humans Idioma: En Revista: Blood Cancer J Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google